Real-world outcomes and prognostic factors of trifluridine/tipiracil plus bevacizumab in metastatic colorectal cancer: a multicenter study in Spain
Authors:
- N. Martínez-LagoNMN. Martínez-Lago
- M. Reboredo LópezMLM. Reboredo López
- M.C. Riesco MartínezMMM.C. Riesco Martínez
- S. López PeraitaSPS. López Peraita
- B. González GómezBGB. González Gómez
- C. Antonilli PérezCPC. Antonilli Pérez
- I. GhanemIGI. Ghanem
- M. Pérez MarteloMMM. Pérez Martelo
- A. López AlfonsoAAA. López Alfonso
- A. Fernández MontesAMA. Fernández Montes
- S. Agraso BustoSBS. Agraso Busto
- A.M. Jiménez GordoAGA.M. Jiménez Gordo
Open Access
- 1 September 2026
- journal article
- Published by Elsevier in ESMO Gastrointestinal Oncology
- Vol. 13
Abstract
No abstract availableThis publication has 31 references indexed in Scilit:
- Impact of KRASG12 mutations on survival with trifluridine/tipiracil plus bevacizumab in patients with refractory metastatic colorectal cancer: post hoc analysis of the phase III SUNLIGHT trialESMO Open, 2024
- Harnessing the Potential of Real-World Evidence in the Treatment of Colorectal Cancer: Where Do We Stand?Current Treatment Options in Oncology, 2024
- Effects and risk factors of TAS-102 in real-world patients with metastatic colorectal cancer, EROTAS-R studyInternational Journal of Clinical Oncology, 2023
- Real-world evidence of trifluridine/tipiracil plus bevacizumab in metastatic colorectal cancer using an administrative claims database in JapanESMO Open, 2023
- P-301 Benefit of adding bevacizumab to trifluridine/tipiracil in different prognostic groups of metastatic colorectal cancer: A Portuguese exploratory analysisAnnals of Oncology, 2023
- P-240 Frequency and management of trifluridine/tipiracil (FTD/TPI) + bevacizumab (BEV)-associated neutropenia in patients with refractory metastatic colorectal cancer (mCRC) in real-world practiceAnnals of Oncology, 2023
- Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upAnnals of Oncology, 2022
- Neutropenia and survival outcomes in metastatic colorectal cancer patients treated with trifluridine/tipiracil in the RECOURSE and J003 trialsAnnals of Oncology, 2020
- TAS-102 plus bevacizumab for patients with metastatic colorectal cancer refractory to standard therapies (C-TASK FORCE): an investigator-initiated, open-label, single-arm, multicentre, phase 1/2 studyThe Lancet Oncology, 2017
- Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal CancerJAMA, 2017